The abstract is read at the publisher; the summary is JClub's.
In phlebotomy-dependent patients with polycythemia vera, rusfertide achieved a clinical response in 77% versus 33% with placebo over weeks 20–32 (P < .0001).
- Why it matters: Frequent phlebotomy and poorly controlled hematocrit in polycythemia vera create ongoing symptom burden and treatment challenges, leaving a need for better erythrocytosis suppression.
- What they did: In VERIFY Part 1a, 293 patients were randomized 1:1, double-blind to rusfertide or placebo (with or without cytoreductive therapy), and outcomes were assessed through week 32.
- The result: Rusfertide reduced mean phlebotomies (0.5 ± 1.2 vs 1.8 ± 1.5; P < .0001), increased hematocrit <45% maintenance (63% vs 14%; P < .0001), and improved PROMIS Fatigue SF-8a and MFSAF TSS7 versus placebo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.